![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV
June 09, 2015 06:30 ET
|
CytoDyn
VANCOUVER, Wash., June 9, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Submits Phase 3 Protocol to FDA After Agreement on Protocol Synopsis
May 04, 2015 16:01 ET
|
CytoDyn
Six Months of Monotherapy With PRO 140 Has Been Effective for HIV Patients in Phase 2b Study
Conference Call Scheduled for May 5 at 1:00 p.m. PT / 4:00 p.m. ET
VANCOUVER, Wash., May 4,...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy - Many HIV Patients in Extension Study With Some Approaching 6 Months
February 03, 2015 08:45 ET
|
CytoDyn
VANCOUVER, Wash., Feb. 3, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program
November 24, 2014 08:00 ET
|
CytoDyn
VANCOUVER, Wash., Nov. 24, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial
October 13, 2014 08:00 ET
|
CytoDyn
VANCOUVER, Washington, Oct. 13, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIV
October 10, 2014 16:26 ET
|
CytoDyn
VANCOUVER, Wash., Oct. 10, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Appoints Carl Dockery to Board of Directors
October 01, 2014 15:43 ET
|
CytoDyn
VANCOUVER, Wash., Oct. 1, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Announces Webcast for Annual Shareholder Meeting
August 15, 2014 15:06 ET
|
CytoDyn
VANCOUVER, Wash., Aug. 15, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
July 31, 2014 08:20 ET
|
CytoDyn
VANCOUVER, Wash., July 31, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...
![CytoDyn Logo](/news-release/logo/298321/0/298321.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A35&size=2)
CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
July 30, 2014 21:51 ET
|
CytoDyn
VANCOUVER, Wash., July 30, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...